Clinical trials: Negative Symptoms in Schizophrenia, open to volunteers
Negative Symptoms in Schizophrenia, Brain Stimulation Intervention
Combining HD-tDCS and iTBS in Treating Negative Symptoms of Schizophrenia
Dysfunction of the dorsolateral prefrontal cortex (DLPFC) is central to the persistence of negative symptoms in schizophrenia. Both HD-tDCS and iTBS targeting the left DLPFC have shown therapeutic benefit.
- Trial name
- NCT07680959
- Testing
- active iTBS followed by active HD-tDCS
- Where
- Taiwan
- Volunteers
- 100 people
- Sponsor
- Tri-Service General Hospital (TSGH)
Schizo-affective Disorder, Non Organic Psychosis
Motivational Intervention for Patients With Schizophrenia
The goal of this clinical trial is to learn if a group therapy called the Positive Emotions Program for Schizophrenia (PEPS) can reduce apathy in adults aged 18 to 60 who have schizophrenia or a related psychotic disorder.
- Conditions
- Schizo-affective Disorder, Non Organic Psychosis, Schizophenia Disorder
- Trial name
- NCT07853079
- Testing
- Positive Emotion Program for Schizophrenia (PEPS), a psychotherapeutic intervention,
- Volunteers
- 88 people
- Sponsor
- University of Geneva, Switzerland
Negative Symptoms of Schizophrenia
Study to Evaluate Efficacy and Safety of Roluperidone in Adult Subjects With Negative Symptoms and Stable Positive Symptoms of Schizophrenia and to Evaluate the Relapse Rate of Roluperidone and Antipsychotic Medications
Evaluate the efficacy, as well as safety and pharmacokinetics, of Roluperidone in improving the negative symptoms of schizophrenia in adult subjects in Phase A of study, followed by Phase B of study to evaluate the relapse rate…
- Trial name
- NCT07565428
- Testing
- Roluperidone, risperidone, aripiprazole
- Where
- 13 sites in United States
- Volunteers
- 380 people
- Sponsor
- Minerva Neurosciences
Schizophrenia, Negative Symptoms in Schizophrenia
Validation of the Lithuanian Version of the BNSS, CDSS, and the SCoRS
This study aims to validate the Lithuanian version of the Brief Negative Symptoms Scale, Calgary Depression Scale for Schizophrenia, and Schizophrenia Cognition Rating Scale in a Lithuanian sample.
- Conditions
- Schizophrenia, Negative Symptoms in Schizophrenia, Depressive Symptoms Due to Primary Psychotic Disorder (Diagnosis), Cognitive Deficit
- Trial name
- NCT06278532
- Testing
- Brief Negative Symptoms Scale, The Calgary Depression Scale for Schizophrenia, The Schizophrenia Cognition Rating Scale
- Where
- 2 sites in Lithuania
- Volunteers
- 200 people
- Sponsor
- Lithuanian University of Health Sciences
Schizoaffecitve Disorder, Schizophrenia and Schizoaffective Disorder
Combination Therapy of Deferiprone and N-Acetylcysteine for Treating Negative Symptoms in Schizophrenia
In following guidelines for studying negative symptoms in schizophrenia, 60 patients aged 18-40, diagnosed with schizophrenia or schizoaffective disorder during the last ten years, will receive a combination of the iron chelator…
- Conditions
- Schizoaffecitve Disorder, Schizophrenia and Schizoaffective Disorder, Schizophrenia and Predominant Negative Symptoms
- Trial name
- IronMan (NCT07759895)
- Testing
- Deferiprone (DFP), N-Acetyl Cysteine (NAC)
- Where
- 2 sites in Israel
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Amit Lotan
Schizophrenia; Negative Type, Transcranial Alternating Current Stimulation
Efficacy of Hi-tACS for Schizophrenia Negative Symptoms
The goal of this clinical trial is to investigate whether Hi-tACS is effective and safe in treating negative symptoms of schizophrenia. Schizophrenic patients will receive treatment (Hi-tACS or shame stimulation) for 2 weeks.
- Trial name
- NCT06888726
- Testing
- High-intensity transcranial alternating current stimulation (Hi-tACS)
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Shanghai Mental Health Center
Schizoaffective Disorder
Synergy Between Physical Activity and Outdoor Green Environments to Reduce the Intensity of Negative Symptoms in Schizophrenia.
Physical activity appears to be a novel and original adjunctive therapeutic approach in the management of patients with schizophrenia.
- Trial name
- SAPIN (NCT07058389)
- Testing
- 8-week outdoor physical activity program, 8-week indoor physical activity program
- Where
- France
- Volunteers
- 45 people
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne
Schizophrenia Disorder
Mechanisms of Sulforaphane Supplementation in Alleviating Negative Symptoms and Cognitive Impairment in Schizophrenia
The goal of this randomized, double-blind, placebo-controlled clinical trial with an open-label extension is to evaluate whether sulforaphane can improve negative symptoms and cognitive impairment, and to explore its underlying…
- Trial name
- NCT07652866
- Testing
- Sulforaphane
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Second Xiangya Hospital of Central South University
Schizophrenia Spectrum Disorder
Transcranial Magnetic Stimulation (TMS) for Negative Symptoms in Schizophrenia Spectrum Disorders
The purpose of this study is to determine if repetitive transcranial magnetic stimulation (rTMS) applied to angular gyrus (AG) will improve negative symptoms and/or other psychosis symptoms in schizophrenia spectrum disorders…
- Trial name
- NCT07290738
- Testing
- TMS
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- The University of Texas Health Science Center, Houston
Negative Symptoms in Schizophrenia, Schizophrenia Disorders
40 Hz Visual Stimulation as an Intervention in Schizophrenia
In schizophrenia, an abnormal reduction in neuronal gamma oscillations (30-100 Hz) is associated with negative symptoms such as cognitive dysfunction.
- Conditions
- Negative Symptoms in Schizophrenia, Schizophrenia Disorders, Schizoaffective Disorder
- Trial name
- GammaSZ (NCT06907420)
- Testing
- Visual stimulation
- Where
- Germany
- Volunteers
- 20 people
- Sponsor
- Technical University of Munich
Schizophrenia
Sex Differences in NMDA-enhancing Treatment of Schizophrenia
Schizophrenia differs between sexes in clinical symptoms and functional outcome. Negative symptoms are the core pathology of this disease. NMDA receptor (NMDAR) dysfunction is a key factor in negative symptoms.
- Trial name
- NCT07122895
- Testing
- NMDAE
- Where
- Taiwan
- Volunteers
- 90 people
- Sponsor
- China Medical University Hospital
Schizophrenia, Cognitive Symptoms
PQQ for Cognitive and Negative Symptoms
Schizophrenia is a complex mental disorder characterized by a range of symptoms, including negative symptoms and cognitive impairments.
- Conditions
- Schizophrenia, Cognitive Symptoms, Negative Symptoms
- Trial name
- NCT07393464
- Testing
- Pyrroloquinoline quinone (PQQ)
- Volunteers
- 70 people
- Sponsor
- Tianjin Anding Hospital
Negative Symptoms in Schizophrenia
Metacognitive Training for Negative Symptoms
There is a clear rationale for developing interventions targeting negative symptoms of schizophrenia as these are a stronger indicator of current and future functioning than positive symptoms and because they respond poorly to…
- Trial name
- NCT06127004
- Testing
- Metacognitive Training for Negative Symptoms (MCT), Supportive Counselling
- Where
- Sweden
- Volunteers
- 90 people
- Sponsor
- Sormland County Council, Sweden
Alzheimer's Disease Psychosis, Parkinson Disease Psychosis
Effect of Food and Age on the Pharmacokinetics of LY03017
This study consists of 2 parts. Part A is a randomized, open-label, 2-period, crossover study to evaluate the food effect of LY03017 in healthy adults.
- Conditions
- Alzheimer's Disease Psychosis, Parkinson Disease Psychosis, Negative Symptoms of Schizophrenia
- Trial name
- NCT06793995
- Testing
- LY03017
- Where
- China
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Luye Pharma Group Ltd.
Schizophrenia Disorder
dACC-Targeted Temporal Interference for Negative and Cognitive Symptoms in Schizophrenia
This randomized, double-blind, sham-controlled trial aims to evaluate the efficacy and safety of dorsal anterior cingulate cortex-targeted temporal interference stimulation in individuals with schizophrenia.
- Trial name
- NCT07658898
- Testing
- Temporal Interference Stimulation
- Where
- China
- Volunteers
- 74 people
- Sponsor
- Shanghai Pudong New Area Mental Health Center, School of Medicine, Tongji University
Hallucinations and Delusions Associated With Alzheimer's Disease Psychosis, Hallucinations and Delusions Associated With Parkinson Disease Psychosis
A Phase 1, MAD Study to Evaluate the Safety, Tolerability and Pharmacokinetics of LY03017
This is a phase 1，randomized, double-blind, placebo-controlled, MAD study to evaluate the safety, tolerability and pharmacokinetics of oral LPM526000133 Fumarate Capsules (LY03017) in healthy adult subjects
- Conditions
- Hallucinations and Delusions Associated With Alzheimer's Disease Psychosis, Hallucinations and Delusions Associated With Parkinson Disease Psychosis, Negative Symptoms of Schizophrenia
- Trial name
- NCT06980207
- Testing
- LY03017
- Where
- China
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Luye Pharma Group Ltd.
Schizophrenia, Negative Symptoms in Schizophrenia
Treatment of Negative Symptoms of Schizophrenia by rTMS
The purpose of this study is to assess the effectiveness of rTMS on the negative symptoms of schizophrenia in real conditions. It will also provide a regulatory framework to rTMS treatments under these conditions.
- Trial name
- SN RENAT (NCT06595654)
- Testing
- repetitive Transcranial Magnetic Stimulation
- Where
- France
- Volunteers
- 124 people
- Sponsor
- Centre hospitalier de Ville-Evrard, France
Schizophrenia Negative Type
Safety and Feasibility of Nasal Delivery of Human Dental Follicle Mesenchymal Stem Cell-Derived Exosomes for Negative Symptoms in Treatment-Resistant Schizophrenia: A Pilot Study
The goal of this clinical trial is to determine the safety and feasibility of nasal delivery of human dental follicle mesenchymal stem cell-derived exosomes in the treatment of negative symptoms of treatment-resistant…
- Trial name
- NCT07485751
- Testing
- hDFSCs-Exo
- Volunteers
- 15 people
- Sponsor
- Zigong Mental Health Center
Schizophrenia, Persistent Negative Symptoms
Stratifying Psychoses for Personalized REpetitive TMS in Persistent NEgative Symptoms Alleviation
In its 2012's release guideline on therapy for schizophrenia, the EMA joined the FDA to acknowledge primary and persistent negative symptoms (PNS) as an unmet need in the treatment of schizophrenia.
- Conditions
- Schizophrenia, Persistent Negative Symptoms, Progressive Periodic Catatonia, Aviation
- Trial name
- SP-RENESA (NCT06184165)
- Testing
- Personalized rTMS
- Volunteers
- 160 people
- Sponsor
- University Hospital, Strasbourg, France
Healthy Control Subjects, Schizophrenia Diagnosis
Understanding Lifespan Trajectories of Social Cognition, Brain Microstructure and Iron Dysregulation in Schizophrenia
This study aims to better understand how schizophrenia may affect social thinking, emotion regulation, brain function, and biological processes over time. Two groups will take part in the study: 1.
- Trial name
- NCT07856381
- Where
- Austria
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Medical University Innsbruck